ibritumomab tiuxetan (Zevalin®)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lymphoma, Non-Hodgkin
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade
Trial Timeline
Jun 1, 2003 → Oct 31, 2005
NCT ID
NCT00168727About ibritumomab tiuxetan (Zevalin®)
ibritumomab tiuxetan (Zevalin®) is a approved stage product being developed by Biogen for Lymphoma, Non-Hodgkin. The current trial status is completed. This product is registered under clinical trial identifier NCT00168727. Target conditions include Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00168727 | Approved | Completed |
Competing Products
20 competing products in Lymphoma, Non-Hodgkin